Anyone read the new 8-K? I still say Sanofi buys them out after PA approval, since POZN will only be a shell corp by then.
"To demonstrate our commitment to stockholder return, we initiated several steps to improve stockholder return going forward, one of which was a distribution of $1.75 per share in December 2013 that represented a tax-efficient return of capital to stockholders. In addition, we are pleased to report that in 2013, shares of the Company rose from $5.01 to $9.85 (before the effect of the distribution), which we believe is attributable to continuing progress with our PA program, signing a major license agreement with Sanofi US, transitioning VIMOVO in the U.S. to Horizon Pharma, and announcing a revised corporate strategy. Specifically, under our new strategy, == POZEN will not undertake any new development programs unless fully paid for by a third party explore ways to continue to distribute excess cash to stockholders in a tax-efficient manner".